Addressing “undruggable” intracellular targets in oncology

About us

We are a biopharmaceutical company devoted to the development of a new class of therapeutics to address unmet medical needs in cancer.

Ribeira Sacra

Libera Bio aims at changing cancer therapy by allowing biologics to cross the cell membrane and reach “undruggable” intracellular targets:  the “Holy Grail” in oncology

Libera Bio leverages  its unique proprietary nanotechnology to hold and protect biologicals (e.g., antibodies) in the blood stream following IV administration and to deliver them intracellularly to tumor cells and to metastatic cells

Libera Bio seeks to maximize the use of its technology with oncology biopharma partners, to offer patients new oncology breakthrough treatments based on intracellular delivery of biologics

Our team

Olivier R. Jarry
Olivier R. Jarry


María José Alonso
María José Alonso Fernández


Desiree Teijeiro
Desirée Teijeiro Osorio


Inma Rodríguez Rodríguez
Inma Rodríguez Rodríguez

Director of Administration & Finance

Daniel Perez Estevez
Daniel Pérez Estévez

Senior Project Manager

Ludmilla David de Moura
Ludmilla David de Moura

Formulation Scientist

Sara Alves Cunha
Sara Alves Cunha

Research Scientist

Cristina Cotelo Costoya
Cristina Cotelo Costoya

Senior Lab Technician

Iñaki Berenguer
Iñaki Berenguer

Board Member

Yolanda Falcón García
Yolanda Falcón García

Board Member

Carla Dosil Bermúdez
Carla Dosil Bermúdez

Board Member

Mario Grande Abascal
Mario Grande Abascal

Board Member

Discover our MPN Technology®

Our patented MPN Technology® enables the discovery and development of new compounds involving intracellular biologics, especially monoclonal antibodies (mAbs), to successfully engage previously undruggable targets.

Imagen paciente


Libera Bio lead target is Mutated KRAS:

KRAS is the Most Frequently Mutated Gene in Human Cancer (e.g. in 9 out of 10 Pancreatic Ductal Adenocarcinoma – PDAC)

The presence of mutant KRAS is associated with poor prognosis and resistance to chemotherapy and targeted treatments (e.g. EGFR)

Despite this important Unmet Medical Need, the development of effective anti-RAS therapies has been marred by more than three decades of failure

Tabla Pipeline


Libera Bio is open to licensing or partnering its MPN Technology® to develop or co-develop new cancer treatments based either on biologics or small molecules.

Partnering contact: Olivier Jarry,


Supported by


ROSP Corunna


Francisco Rañal

Inquiries from potential investors in the next round of funding of Libera Bio are welcome.

Investors Relations:


Programa Investigo
Axudas IGAPE Galicia Exporta Empresas
Axudas IGAPE para novos emprendedores
Bono de innovación

Persoal cofinanciado pola Xunta de Galicia ao abeiro da Resolución da Axencia Galega de Innovación do 29 de xullo de 2021 (Programa Talento Sénior)

Xunta Galicia
Talento senior


Contact us and follow us on social media

Libera Bio Santiago de Compostela

Edificio Emprendia
Avenida do Mestre Mateo 2
15706 Santiago de Compostela, A Coruña (Spain)

Libera Bio New York

15 Rockridge Rd
Larchmont NY 10538-3918